Cormorant Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cormorant Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,080,000	Closed	-$3.06M	–	86
2016 Q1	$3.06M	Hold	1,080,000	–	–	0.46%	53
2015 Q4	$11.1M	Hold	1,080,000	–	–	1.33%	30
2015 Q3	$12.3M	Buy	1,080,000 +400,000	+59%	+$5.34M	1.97%	14
2015 Q2	$10.2M	Hold	680,000	–	–	1.35%	24
2015 Q1	$6.14M	Sell	680,000 -120,000	-15%	-$1.24M	0.95%	35
2014 Q4	$9.73M	Sell	800,000 -300,000	-27%	-$3.31M	1.5%	22
2014 Q3	$10.8M	Sell	1,100,000 -68,000	-6%	-$833K	2.21%	10
2014 Q2	$14.9M	Hold	1,168,000	–	–	3.95%	7
2014 Q1	$12.4M	Buy	1,168,000 +900,000	+336%	+$9.6M	2.84%	14
2013 Q4	$2.04M	Buy	+268,000	New	+$1.7M	0.59%	28

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Cormorant Asset Management's BCRX Position: Q2 2016 in Review

Cormorant Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2016, closing a stake of 1,080,000 shares — an estimated $3.06M sold.

Cormorant Asset Management first reported a position in BCRX in Q4 2013 and held it in 10 quarters. The position peaked at $14.9M in Q2 2014. 100 funds tracked by Wall St. Rank hold BCRX as of Q2 2016.

Cormorant Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Cormorant Asset Management sold 1,080,000 BioCryst Pharmaceuticals shares in Q2 2016, an estimated $3.06M.
Cormorant Asset Management first reported a position in BioCryst Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Cormorant Asset Management's BioCryst Pharmaceuticals position peaked at $14.9M in Q2 2014.
100 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2016.

Based on Cormorant Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.